Rocuronium bromide

Rocuronium bromide

Systematic (IUPAC) name
1-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1H-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidinium bromide
Clinical data
AHFS/Drugs.com	monograph
Pregnancy cat.	?
Legal status	POM (UK)
Routes	Intravenous
Pharmacokinetic data
Bioavailability	NA
Protein binding	~30%
Metabolism	some de-acetylation
Half-life	66–80 minutes
Excretion	Unchanged, in bile and urine
Identifiers
CAS number	119302-91-9 Y
ATC code	M03AC09
PubChem	CID 441290
DrugBank	APRD01221
UNII	I65MW4OFHZ N
ChEMBL	CHEMBL1201244 N
Synonyms	[3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enyl-2,3,4,5-tetrahydropyrrol-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
Chemical data
Formula	C32H53N2O4+
Mol. mass	529.774 g/mol
N(what is this?)  (verify)

Rocuronium (Zemuron, Esmeron) is an aminosteroid non-depolarizing (that is, it does not cause initial stimulation of muscles before weakening them) neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron in the United States and Esmeron in most other countries.

There is considered to be some risk of allergic reaction to the drug in occasional patients (particularly those with asthma), but a similar incidence of allergic reactions has been observed by using other members of the same drug class (non-depolarizing neuromuscular blocking drugs). The drug is commonly used in modern anaesthesia.

The γ-cyclodextrin derivative sugammadex (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium.